Premium
Assessment by antipyrine test of bupropion enzymic induction in elderly depressed patients
Author(s) -
Bourin M.,
Colin J. N.,
Kergueris M. F.,
Ortega A.,
Nebout T.,
Peck A. W.
Publication year - 1988
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470030408
Subject(s) - bupropion , inducer , antidepressant , medicine , liver enzyme , enzyme inducer , pharmacology , endocrinology , anesthesia , chemistry , enzyme , biochemistry , pathology , smoking cessation , hippocampus , gene
Abstract Bupropion, a novel antidepressant drug, is known to be a moderate hepatic metabolism‐inducer in rodents at high doses but not in young human volunteers. Eleven elderly depressed patients (mean age 76·9 ± 8·7 years) entered in the study and received 100 mg of bupropion t.i.d. for 28 days. An antipyrine test was performed before and at day 28 of therapy. Antipyrine was taken orally (15 mg/kg) at 8 a.m. and blood samples were drawn at 11 a.m., 2, 5, and 8 p.m. Plasma levels were assayed using a GLC method. Results show a slight but significant increase of apparent clearance (+30 per cent) and decrease in the half‐life (–14 per cent) of antipyrine. Difference between these results and previous results in young volunteers might be explained by the usual decrease of hepatic function described in elderly patients. Bupropion can be considered in elderly people as a slight hepatic enzyme‐inducer.